Drug Discovery Through Gene Regulation
February 2, 2020
While much of targeted drug discovery has focused on inhibiting or otherwise changing the function of abnormal genes and proteins, many more diseases could be addressed by modulating the expression of both abnormal and normal genes, turning them on or off, up or down. Syros CSO Eric Olson, Ph.D., spoke with Illumina’s Genomics Podcast about how Syros is applying this concept to enable a paradigm shift in drug discovery.
Listen to the podcast here.